linjc16/ctgov huggingface dataset:
Multivitamin Adherence Following Bariatric Surgery

Study Overview
=================
Brief Summary
-----------------
Additional micronutrient supplementation is required due to the changes in the gastrointestinal anatomy and physiology following bariatric surgery along with decreased dietary intake and rapid weight loss. Good adherence to post-operative vitamins is essential to maintain healthy vitamin levels in the body following bariatric surgery. The hypothesis of this study is that patients receiving a weekly survey intervention will have better adherence to post-operative vitamins.

Official Title
-----------------
Adherence to Multivitamin Use Following Bariatric Surgery for Weight Loss

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Weekly Internet surveys


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Planning to undergo a Roux En Y Gastric Bypass or Sleeve Gastrectomy at Wake Forest Baptist Health Exclusion Criteria: Admission for a psychiatric event in the past year History of nausea and/or significant complaint of post-operative nausea History of stricture and/or significant complaint of post-operative stricture History of ulcer and/or significant complaint of post-operative ulcer History of major depression or psychiatric disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Participants are assigned to either receive the weekly survey or not.
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Weekly surveys<br>Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment. | Behavioral: Weekly Internet surveys<br>* Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.<br>|
| No Intervention: No Survey<br>Subjects will take the multivitamin. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to Multivitamin | Percent of anticipated number of doses the patient has taken, as recorded by a Medication Event Monitoring System (MEMS) cap. | 50 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bariatric surgery, multivitamin, weight loss, adherence
Pattern and Surgical Treatment of Parotid Gland Neoplasms

Study Overview
=================
Brief Summary
-----------------
in these study we analyze pattern of parotid gland neoplasms according to histopathological types, most common type clinical presentation and type of surgical treatment(superficial parotidectomy or total parotidectomy radical parotidectomy

Detailed Description
-----------------
aim of study is to analyze pattern of parotid glands neoplasms in upper Egypt as regard 1)age 2) sex , 3) clinical presentation :symptom (parotid lump, pain and facial nerve paralysis) and sign (tenderness, fixation of parotid lump and presence of lymph nodes) 4)histopathological types:(benign or malignant 5)surgical options :superficial parotidectomy, total parotidectomy or radical parotidectomy 6)postoperative complications :facial nerve dysfunction, fistula ,recurrence 7) mortality rate all data will be recorded, tabulated , and statistically analyzed .

Official Title
-----------------
Pattern and Outcome of Surgical Treatment of Parotid Gland Neoplasms in Upper Egypt(Retrospective Study)

Conditions
-----------------
Parotid Gland Neoplasm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patient with parotid neoplasm with any age and sex at the period between may2015 to May2021 presented in upper Egypt enrolled in this study all the data will recorded ,tabulated and statistically analyzed emphasizing on: 1) age. 2)sex. 3)clinical presentation: symptoms (parotid lump ,pain and facial nerve paralysis sign (tenderness ,fixations of parotid lump and presence of lymph nodes) . 4)surgical options : - superficial parotidectomy (partial superficial parotidectomy or formal superficial parotidectomy) . total parotidectomy . radical parotidectomy. 5)postoperative complications: facial nerve dysfunction, fistula , recurrence) . 6) mortality rate. Exclusion criteria: No exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| parotid gland neoplasm in upper Egypt<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pattern of parotid gland neoplasms |  | after 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parotid
Optic Nerve Sheath Diameter in Patients Undergoing Palatoplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the change of the optic nerve sheath diameter according to the change of the neck position in pediatric patients undergoing palatoplasty.

Detailed Description
-----------------
Palatoplaty is performed under neck extension in patients with cleft palate. The purpose of this study is to evaluate the effect of neck extension on the ultrasonographic optic nerve sheath diameter during palatoplasty.

Official Title
-----------------
Effect of Neck Extension on Optic Nerve Sheath Diameter in Patients Undergoing Palatoplasty

Conditions
-----------------
Cleft Palate

Intervention / Treatment
-----------------
* Procedure: Neck extension


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have undergone a palatoplasty with cleft palate and who are 6 months or older and under 24 months Patients who agree to voluntarily participate in this study Patients with ASA class 1-2 Exclusion Criteria: History of diagnosis of neurologic or ophthalmic disease History of neurosurgery or ophthalmic surgery Patients who refused to participate in clinical studies

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 24 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in optic nerve sheath diameter | Difference between the optic nerve sheath diameter measured during supine position without neck extension and the optic nerve sheath diameter measured during supine position with neck extension in patients undergoing palatoplasty | 10 minutes after neck extension | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in optic nerve sheath diameter | Difference between the optic nerve sheath diameter measured during supine position without neck extension and the optic nerve sheath diameter measured during supine position with neck extension in patients undergoing palatoplasty | at end of surgery with the neck extended |
Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance

Study Overview
=================
Brief Summary
-----------------
The research will examine psychotherapists' preferences for theoretical client characteristics, such as age, gender, personality characteristics and symptoms. The research will also examine the preferences' influence on the therapeutic alliance, from the therapist's and the client's point of view.

Official Title
-----------------
Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance

Conditions
-----------------
Diagnosis, Psychiatric, Outpatient Followup of Psychiatric Problem

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients over the age of 18, Hebrew speakers, Not in a psychotic state. Exclusion Criteria: Psychotic state, Under the age of 18, Not qualified to answer the questions, Don't speak any Hebrew at all.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive correlation between preferences- characteristics match and therapeutic alliance. | The match between therapists' preferences ant their client's characteristics will correlate positively with the measures of therapeutic alliance. | 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychotherapy, Preferences
Exercise Time in Sedentary Middle-aged Female

Study Overview
=================
Brief Summary
-----------------
The exercise time is an important factor among the medical guides for weight loss; however, there is still little knowledge about exercise duration paths in middle-aged and older women. The present study aimed to determine the effects of the interval training on weight loss and lipid profile, and to compare its efficiency with the continuous training.

Detailed Description
-----------------
Participants included sedentary women (age 45-75 years) with overweight or obesity (n= 115). They were randomly divided into two groups including continuous exercise, and interval exercise. The weight assessment parameters including change in weight and body composition, blood sample tests were performed pre- and three month post-intervention.

Official Title
-----------------
Response Of Weight And Lipid Profile To Exercise Time In Sedentary Overweight/Obese Middle-Aged And Older Women

Conditions
-----------------
Weight Loss

Intervention / Treatment
-----------------
* Other: Exercise time


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sedentary lifestyle Good Health Weight stability Exclusion Criteria: *Abnormality or history of Disease

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group I<br>Study group I (57 participants) received the continuous training of exercise time. | Other: Exercise time<br>* Continuous training, Interval training<br>|
| Active Comparator: Group II<br>Study group II (58 participants) received the interval training of exercise time. | Other: Exercise time<br>* Continuous training, Interval training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDL-c |  | 3 month |
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

Study Overview
=================
Brief Summary
-----------------
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C. The objectives were to identify factors associated with sofosbuvir/daclatasvir plasma concentrations variations and to evaluate their impact on viral kinetics.

Official Title
-----------------
Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay

Conditions
-----------------
Hepatitis C

Intervention / Treatment
-----------------
* Drug: Sofosbuvir/daclatasvir with or without ribavirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hepatitis C virus infection treated with sofosbuvir/daclatasvir Patients with at least one measurement of sofosbuvir or daclatasvir plasma concentration Follow-up of at least 3 months after the end of treatment Exclusion Criteria: Patients with severe renal failure (estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2) Patients with liver transplantation during therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sofosbuvir/daclatasvir<br>Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014 | Drug: Sofosbuvir/daclatasvir with or without ribavirin<br>* Direct-acting antiviral treatment for hepatitis C virus infection<br>* Other names: Combination of sofosbuvir and daclatasvir with or without ribavirin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sofosbuvir/daclatasvir plasma concentration |  | Sofosbuvir/daclatasvir plasma concentrations were measured at week 4, 8, 12 and 24 during therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HCV viral load |  | At treatment initiation, at week 4, 8, 12 and 24 of therapy and 12 weeks after the end of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cirrhosis, Direct acting antiviral agents, Hepatitis C, Pharmacological monitoring
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Official Title
-----------------
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

Conditions
-----------------
Acute Myelogenous Leukemia

Intervention / Treatment
-----------------
* Biological: GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months. No prior therapy except leukapheresis or less than 72 hours of hydroxyurea. Exclusion Criteria: Prior myelodysplastic disorder, or treatment-related leukemia. Prior myeloproliferative disease. Acute promyelocytic leukemia (APL). Prior chemotherapy for a malignant or nonmalignant disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AML, Acute Myelogenous Leukemia, GVAX, Vaccine, Stem Cell Transplant, Autologous
the Effect of Music on Pain and Women Satisfaction During Diagnostic Outpatient Hysteroscopy in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to demonstrate the value of music in diagnostic outpatient hysteroscopy on patients' level of pain and satisfaction in postmenopausal women

Official Title
-----------------
the Effect of Music on Pain and Women Satisfaction During Diagnostic Outpatient Hysteroscopy in Postmenopausal Women: a Randomized Controlled Trial

Conditions
-----------------
Hysteroscopy

Intervention / Treatment
-----------------
* Other: Music
* Other: No music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding or abnormal ultrasound ﬁndings) Exclusion Criteria: patients with cervical pathology retroverted uterus (detected by transvaginal ultrasound) previous cervical surgery patients with severe vaginal bleeding
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: music group<br>In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor. | Other: Music<br>* In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.<br>|
| Other: non-music group<br>Participants in the non-music group will undergo diagnostic outpatient hysteroscopy in the same setting and standard procedure without listening to any music. | Other: No music<br>* Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of pain | Pain intensity will be assessed by visual analog scale during the procedure. visual analog scale ranging from 0 to 100 | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of pain | Pain intensity will be assessed by visual analogue scale during the procedure.visual analogue scale ranging from 0 to 100 | 20 minutes |
Tracking Results of Ablations to Combat AF Registry

Study Overview
=================
Brief Summary
-----------------
This is a global retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing ablations for the treatment of Atrial Fibrillation.

Official Title
-----------------
A Multicenter Patient Registry for Outcomes From Comprehensive Ablation Treatments of Atrial Arrhythmias

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: AtriCure Isolator® Synergy™ Surgical Ablation System
* Device: AtriCure AtriClip® LAA Exclusion System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a history of paroxysmal (intermittent), persistent or long-standing persistent atrial fibrillation and who have undergone or will undergo ablation treatment Patient >= 18 years of age Exclusion Criteria: Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager Subject with exclusion criteria required by FDA or local governance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: AtriCure Isolator® Synergy™ Surgical Ablation System|The AtriCure Isolator® Synergy™ Surgical Ablation System is used in the Maze IV procedure for the treatment of Atrial Fibrillation.|
|Device: AtriCure AtriClip® LAA Exclusion System|The AtriCure AtriClip® LAA Exclusion System is used to exclude the Left Atrial Appendage.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's AF burden 6-month after receiving the ablation procedure | Collect patient data on Atrial Fibrillation burden after the ablation procedure as documented by long term event monitoring or identified during the exam after a six-month recovery period. | 6 months | 
| Adverse events of the ablation procedure as atrial fibrillation management | Collect data on adverse events occurred during and post operation to assess the safety of the ablation procedure. | 1 year |